A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus
© Chunduri et al; licensee BioMed Central Ltd. 2011
Received: 18 November 2010
Accepted: 21 January 2011
Published: 21 January 2011
We’re sorry, something doesn't seem to be working properly. Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
The major hurdle in the treatment of Human Immunodeficiency virus type 1 (HIV-1) includes the development of drug resistance-associated mutations in the target regions of the virus. Since reverse transcriptase (RT) is essential for HIV-1 replication, several nucleoside analogues have been developed to target RT of the virus. Clinical studies have shown that mutations at RT codon 65 and 74 which are located in β3-β4 linkage group of finger sub-domain of RT are selected during treatment with several RT inhibitors, including didanosine, deoxycytidine, abacavir and tenofovir. Interestingly, the co-selection of K65R and L74V is rare in clinical settings. We have previously shown that K65R and L74V are incompatible and a R→K reversion occurs at codon 65 during replication of the virus. Analysis of the HIV resistance database has revealed that similar to K65R+L74V, the double mutant K65R+L74I is also rare. We sought to compare the impact of L→V versus L→I change at codon 74 in the background of K65R mutation, on the replication of doubly mutant viruses.
Proviral clones containing K65R, L74V, L74I, K65R+L74V and K65R+L74I RT mutations were created in pNL4-3 backbone and viruses were produced in 293T cells. Replication efficiencies of all the viruses were compared in peripheral blood mononuclear (PBM) cells in the absence of selection pressure. Replication capacity (RC) of mutant viruses in relation to wild type was calculated on the basis of antigen p24 production and RT activity, and paired analysis by student t-test was performed among RCs of doubly mutant viruses. Reversion at RT codons 65 and 74 was monitored during replication in PBM cells. In vitro processivity of mutant RTs was measured to analyze the impact of amino acid changes at RT codon 74.
Replication kinetics plot showed that all of the mutant viruses were attenuated as compared to wild type (WT) virus. Although attenuated in comparison to WT virus and single point mutants K65R, L74V and L74I; the double mutant K65R+L74I replicated efficiently in comparison to K65R+L74V mutant. The increased replication capacity of K65R+L74I viruses in comparison to K65R+L74V viruses was significant at multiplicity of infection 0.01 (p = 0.0004). Direct sequencing and sequencing after population cloning showed a more pronounced reversion at codon 65 in viruses containing K65R+L74V mutations in comparison to viruses with K65R+L74I mutations. In vitro processivity assays showed increased processivity of RT containing K65R+L74I in comparison to K65R+L74V RT.
The improved replication kinetics of K65R+L74I virus in comparison to K65R+L74V viruses was due to an increase in the processivity of RT containing K65R+L74I mutations. These observations support the rationale behind structural functional analysis to understand the interactions among unique RT mutations that may emerge during the treatment with specific drug regimens.
Multidrug resistance (MDR) mutations evolve due to incomplete suppression of viral replication during treatment of HIV-infected patients. The preferential selection and persistence of one mutation relative to another, however, is not well understood. Specifically, the rare combinations of mutations have not been analyzed in depth. As novel nucleoside reverse transcriptase inhibitors (NRTI) continue to evolve and be employed as a component of highly active antiretroviral therapy (HAART), rare combinations and/or new combinations of RT mutations will appear more frequently.
Reverse transcriptase (RT) mutations K65R and L74V/I are selected by several antiretroviral drugs and play important roles in drug susceptibility and/or maintenance of viral load during treatment of HIV-1-infected individuals. Interestingly, prevalence of these mutations in relation to M184V is strikingly low. Analysis of database (Monogram Biosciences, South San Francisco, CA) have shown that thymidine analogue mutations (TAMs) and M184V are the most common (>25%) followed by L74V/I (11%) and K65R (3.3%) mutations during clinical trials [1–3]. Since the prevalence of these mutations have been looked in conjunction with other multidrug-selected mutations, it is not possible to predict the interaction among various mutations and subsequent genotypes.
The selection of K65R and L74V on the same genome is extremely rare. Interesting observation regarding the absence of selection of K65R and L74V in the same virus by Bazmi et al. (2000) was revealed during passaging of HIV-1 in the presence of (-)-β-D-dioxolane-guanosine (DXG). This study showed that K65R and L74V were selected during passaging of HIV-1 LAI in the presence of DXG albeit in different viral genome . We subsequently demonstrated that mutations K65R and L74V are mutually exclusive and a R→K reversion occurs at RT codon 65 during replication of virus in peripheral blood mononuclear (PBM) cells in the absence of drugs . These analyses provided the potential mechanism for the extreme rarity of the double mutant in HIV-infected patients. Similar to K65R+L74V, K65R+L74I is also rarely observed in the absence of other mutations [6–8]. Structurally, valine has two methyl groups, whereas isoleucine's branches are one methyl and one ethyl group. Therefore, isoleucine (Ile or I) has an additional methyl group as a side chain in comparison to valine (Val or V). As a consequence Ile has a longer side chain. We hypothesized that L74I in combination with K65R will have a more profound effect on RT resulting in a highly crippled virus. To delineate the differences between valine and isoleucine changes at codon 74 in the background of K65R, we created site directed mutants and performed replication kinetics assays in PBM cells and MT-2 cells, and in vitro RT processivity assays. We show here that in contrast to our hypothesis, the L74I change leads to a replication competent virus in the background of K65R. Additionally, virion-associated RT containing K65R+L74I mutations showed increased processivity in a single round of reverse transcription in comparison to K65R+L74V.
Chemicals and medium
Radionucleotides, (methyl-3H)dTTP and [α-32P]dTTP were purchased from Perkin Elmer, (Shelton, CT); poly(rC)-poly(dG)12-18 was purchased from Amersham Pharmacia Biotech, (Piscataway, NJ); and Polynucleotide poly(rA) and primer oligo(dT)12-18 were purchased from Boehringer Mannheim (IN). The oligonucleotides used for mutagenesis were synthesized and high pressure liquid chromatography purified by Diversified Biopharma Solutions Inc. (Loma Linda, CA). Complete Dulbecco's Modified Eagles Medium (DMEM) containing 10% heat inactivated fetal bovine serum (FBS) and penicillin/streptomycin was used to grow 293T cells. Complete RPMI medium containing 20% FBS, 26 IU of IL-2, penicillin/streptomycin and glutamine was used to culture Peripheral blood mononuclear (PBM) cells. MT-2 cells were grown in RPMI containing 10% FBS, penicillin/streptomycin and glutamine.
Cells and virus
PBM cells were prepared from Buffy coats received from commercial vendors (Red Cross and LifeSouth Community Blood Center, Atlanta, GA) using Ficoll gradients. Primary human embryonic kidney cells 293T, indicator cell line HeLa-CD4-LTR-β-galactosidase and proviral clone pNL4-3 [9, 10] were obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institute of Health.
Site-specific mutagenesis and generation of mutant viruses
Various single point mutants were created in the background of proviral clone pNL4-3 by using pALTER-1 mutagenesis system of Promega (Madison, WI) according to manufacturer's guidelines and our previously described protocols [11, 12]. Mutagenic oligonucleotide pNL74I 5'-GAAATCTACTATTT TTCTCCAT-3' was used to create L74I mutation in the background of NL4-3 (wild type) and NL4-3 containing K65R mutation. Mutants K65R, L74V, and K65R+L74V that have been previously analyzed for replication capacity and in vitro RT processivity were used as controls [12, 13]. Viruses were produced using SuperFectR reagent (Quiagen, Valencia, CA) and manufacturer's guidelines. Cells (293T) were split into 60 × 10 mm dishes 24 h-48 h prior to transfection. To generate virus the complex containing 10 μg of DNA in 150 μl of serum-free medium and 30 μl of SuperFect reagent was incubated at room temperature for 10 min. One ml of complete DMEM was added drop by drop onto 293 cells that were washed once with phosphate buffer saline (PBS). Cells were incubated at 37°C in the presence of 5% CO2 for 3 h. The remaining medium-complex was removed and the cells were washed with 4 ml of PBS. Four ml of complete DMEM was added and dishes were incubated for 72 h-96 h. Culture supernatants were collected and centrifuged for 5 min at 833g (g = 1.2) to pellet any debris. Culture supernatants were filtered (0.22 μm) and saved in aliquots of 0.5 ml and 1 ml at -80°C. Viral RNA was isolated by QiAamp® viral RNA mini kit (Qiagen Sciences, Valencia, CA). RT PCR was performed using Superscript™ III one-step RT PCR system (Invitrogen, Carlsbad, CA). All the stock viruses were confirmed by sequencing viral RNA using primer 74F, 5'-GTAGGACCTACACCTGTCAAC-3' .
Quantification of virus
Both HIV-1 antigen p24 concentrations as well as RT activity for each stock virus were determined as described previously [12, 15]. Briefly, a ntigen p24 determination was done according to the manufacturer's protocol using Antigen p24CA ELISA kit (NCI, Frederick, MD). To determine RT activity, one ml of each virus was centrifuged for 2 h at 15,000 rpm in a refrigerated centrifuge [Heraeus Instruments Corp., Model, Biofuge 15R; Rotor, 3743]. Pelleted virions were lysed with 50-100 μl of virus solubilization buffer (0.5% Triton X-100, 50 mM Tris, pH 7.8, 800 mM NaCl, 0.5 mM PMSF, 20% Glycerol), 10 μl of samples in triplicate were mixed with 75 μl of RT assay buffer (60 mM Tris, pH 7.8, 12 mM MgCl2, 6 mM Dithiothreitol, 7 μg dATP) in the presence of 450 ng of poly (rA)-Oligo (dT) and 5 μCi of methyl-3H TTP and reactions were incubated at 37°C for 2 h. Entire reaction mixture was overlaid on DE81 filter (Whatman, GE Healthcare). Filters were washed 3 times with 2X SSC buffer, 2 times with absolute alcohol, air dried and the radioactivity was measured in scintillation fluid.
Determination of viral titer
Viruses produced in 293T cells were quantified in HeLa-CD4-LTR-β-galactosidase cell lines as described elsewhere . Briefly, 20-30% confluent cells in 12-well plate were infected with stock viruses containing 1, 10 and 100 ng antigen p24 in the presence of 20 μg of DEAE-dextran (Pharmacia) per ml. The plates were rocked intermittently every 30 min until 120 min and then 1 ml of DMEM with 10% calf serum was added to each well. After 48 h, the medium was removed and the cells were fixed at room temperature with 2 ml of phosphate-buffered saline (PBS) containing 1% formaldehyde and 0.2% glutaraldehyde for 5 min. The cells were washed four times with PBS and incubated for 50 min at 37°C in 500 μl of a solution of 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM MgCl2, and 0.4 mg of X-Gal per ml. The reaction was stopped by decanting the staining solution and washing the cells thrice with PBS. Blue cells were counted at 100X magnification of a light microscope. Infectious units were calculated by counting the number of blue colonies in each dilution and the amount of HIV-1 p24 capsid antigen by ELISA. The amount of virus (antigen p24) required to infect 1 cell was considered equivalent to 1 infectious unit (IU) or multiplicity of infection (MOI) 1.
Replication kinetics assays
Healthy donor's PBM cells were infected at various MOIs (0.001, 0.01 and 1.0) based upon the IU. Replication kinetics assays were performed by infecting 10 × 106 PHA-stimulated PBM cells with equivalent amount of viruses. Culture supernatants were collected every other day until day 14 to determine antigen p24, RT activity and genomic RNA sequence. In a parallel experiment 3.0 × 106 MT-2 cells (0.5 × 106/ml) were infected with 0.001 IU of various viruses and replication kinetics were measured by monitoring RT activity until day 14.
Quantification of R→K reversion at RT codon 65
We have demonstrated previously that RT containing K65R+L74V is highly unstable and a rapid R→K reversion occurs at RT codon 65 . Homogenous populations of both double mutant viruses, K65R+L74V and K65R+L74I were produced in 293T cells. PHA-stimulated PBM cells (10 × 106) were infected with 0.1 MOI of viruses and reversion of viruses was followed between day 7 and day 28 by sequencing equivalent amount of cDNA products synthesized from viral RNA isolated from culture supernatants at different time points. The relative reversion ratios for double mutants were calculated by comparing the peak heights of nucleotides A/G (AA A/AG A) and T/G (T TA/G TA) at RT codons 65 and 74 respectively. In order to quantify reversion rates, various ratios of wild type cDNA (K65) and mutated K65R cDNA were mixed and sequenced; peak heights were measured for both nucleotides and percentage reversion was calculated according to our previously published protocols . To confirm the ratios of peak heights observed, we performed population cloning in Topo TA cloning vector PCRR2.1 (Carlsbad, CA) by cloning RT PCR products and sequencing 20 clones at each time point.
In vitro RT processivity assay
Since various viral (nucleocapsid proteins, integrase) and host factors (p53 and cellular topoisomerase) have been shown to interact with HIV-1 RT [16–23], we compared virion-associated RTs of mutant and wild type viruses in all of our assays. RT processivity assays were performed as described elsewhere [13, 24, 25]. Briefly, stock viruses supernatants containing 1500 to 3000 ng equivalent of antigen p24 were centrifuged at 16,000 rpm for 2 h at 4°C. RT was dislodged from the pelleted virions by the treatment of 50 μl of 0.5% NP40. The RT activity was determined using homopolymer template/primer [poly rA-oligo d(T)] and α-32P dTTP according to published protocols [12, 15, 25]. Different amount (2 μl, 4 μl, 6 μl) of RT lysates were incubated with 1 μg/ml of poly (rA) and 0.16 μg/ml of oligonucleotide (dT) in the presence of an assay mixture containing 60 mM Tris (pH 7.8), 75 mM KCl, 5 mM MgCl2, 0.1% NP40, 1 mM EDTA, and 4 mM DTT at 37°C for 30 min in the absence of radiolabeled dTTP. After the formation of Template-primer-enzyme complex, cDNA synthesis was initiated by the addition of 50 μCi of [α-32P] dTTP/ml and 50-fold excess of trap [poly (rC)-oligo (dG)]. The reactions were terminated after 180 min by placing the tubes in ice slurry and addition of the equal volume of buffered phenol. cDNA products were extracted once with phenol:chloroform (25:24) followed by one extraction with chloroform only. In order to normalize the volume of extracted cDNA, equivalent amount of top layer (DNA) was collected after centrifuging the mixture of phenol and DNA solution. The cDNA was precipitated with 2.5 volumes of absolute alcohol in the presence of 2.5 M ammonium acetate. After desalting the precipitated DNA with 70% alcohol, the pellet was vaccume-dried and suspended in 8 μl of sterilized water. Half of the DNA was mixed with formamide-dye mixture and heated at 95°C for two minutes in a water bath. The purified products were run on 6% polyacrylamide sequencing gel electrophoresis at 30 W for 2 h. The wet gels were exposed to autoradiography for 30 min to 2 hr. To determine relative density of bands in the gel, we scanned group of bands using Bio Image Intelligent Quantifier® software (Bio Image Systems, Inc, Jackson, MI).
To compare the replication capacity (RC) of mutant viruses in relation to wild type virus, RC values for 3 independent replication assays were calculated for mutant viruses. A paired analysis with student t-test was performed and p ≤ 0.5 were considered as significant difference. In order to control the variations among sequencing reactions and observed peak heights in chromatograms, we performed regression analysis between observed and expected peak heights for two nucleotides at the same locus . Statistical analysis was conducted to determine the differences in processivity between WT and mutant viruses or among mutant viruses K65R+L74V and K65R+L74I during a single processivity cycle. This analysis was designed to test the hypothesis that for wild type and mutant RTs, cDNA density decreases at the same rate as DNA band number increases. Three to five independent processivity assays were performed for each RT and statistical values that include mean, median, standard deviation and maximum and minimum were obtained. A paired analysis with t-test was performed to compare the density of cDNA products generated by various RTs and p ≤ 0.05 was considered significant difference .
A Leu→Ile change at RT codon 74 leads to a replication competent virus in the background of K65R (K65R+L74I) in PBM cells
Comparison of replication kinetics of mutant viruses in MT-2 cells
Comparison of R→K reversion dynamics at codon 65 for doubly mutant K65R+L74V and K65R+L74I
Increased in vitro processivity of K65R+L74I RT in comparison to K65R+L74V RT
CDNA density obtained for Wild type, K65R+L74V and K65R+L74I RTs
Group of cDNA Bandsa
1153 ± 103.0
1125 ± 79.0
1152 ± 102.0
1375 ± 80.5
1282 ± 82.5
1332 ± 72.5
1545 ± 100.0
1309 ± 89.0
1549 ± 95.5
1592 ± 94.5
1202 ± 102.5
1497 ± 70.5
1521 ± 76.5
1059 ± 109.0
1321 ± 56.5
1483 ± 76.5
854 ± 74.0
1018 ± 68.5
1410 ± 46.0
655 ± 65.0
789 ± 109.5
1314 ± 55.0
572 ± 72.5
672 ± 82.0
1254 ± 74.0
614 ± 84.0
962 ± 57.5
362 ± 62.5
727 ± 73.0
606 ± 102.0
Certain combinations of RT mutations are rare in the clinic and it is conceivable that a specific combination will never be observed due to severe structural-functional constraints on RT which do not allow a viable virus. We have shown previously that K65R and L74V mutations are incompatible and a 65R→K reversion occurs during the replication of double mutant virus K65R+L74V . Biochemical analysis revealed that doubly mutant RT has a significant decreased ability to incorporate natural dNTPs in comparison to wild type RT and K65R RT . Also, virion-associated RT containing these two mutations had a significant decrease in RT processivity in comparison to WT, K65R and L74V RTs . Recent careful screening of an HIV-1 database has revealed the importance of a less studied L→I mutation at codon 74. Similar to L74V, the selection of L74I is also rare in the same HIV-1 genome that contains K65R mutation [1, 6, 8]. Since 74I possesses an additional side chain as a methyl group in comparison to 74V, we expected a more pronounced processivity defect with the RTs containing both mutations K65R+L74I in the same genome. In contrast, we show here that the K65R+L74I viruses replicated much more efficiently in PBM cells than those containing K65R+L74V. In fact in MT-2 cells, viruses containing K65R+L74I mutations showed a better replication capacity, suggesting the role of higher dNTP concentrations of MT-2 cells in conferring an increased replication of mutant viruses. In parallel to improved replication capacity of K65R+L74I viruses, our reversion assays showed a significant decrease in R→K reversion at codon 65 in K65R+L74I viruses in comparison to those containing K65R+L74V mutation (Figure 4). We speculate that a decreased R→K reversion in K65R+L74I viruses is due to a decreased survival pressure as compared to the viruses with lethal combination K65R+L74V.
In conjunction with improved replication kinetics of K65R+L74I viruses, RT containing K65R+L74I showed a significant increase in in vitro processivity in comparison to K65R+L74V RT. Evidently, the side chain of isoleucine improved the processivity of K65R+L74I RT during incorporation of 'T' nucleotide (α-32P TTP) rather than imparting a more severe structure-function constraint compared to K65R+L74V RT. Previous mutagenic study of RT codon 74 demonstrated that apart from L74M, other changes L74A, L74G, L74D did not yield enough RT to yield a viable virus . These studies emphasized the effect of severe structure-function constraint of side chains of amino acids at RT codon 74. In contrast, our analysis show that L→I change at RT codon 74 improves RCs of viruses in the background of K65R, suggesting that the specific interaction among amino acid residues at RT codon 65 and 74 could have a different structural constraint. A recent study comparing binary structures of WT and M184I RTs showed that Ile mutation at position 184 with a longer and more rigid beta-branched side chain possibly deforms the shape of the dNTP binding pocket which can restrict dNTP binding resulting in inefficient DNA synthesis at low dNTP concentrations .
RT codons 65 and 74 are parts of the highly flexible β3-β4 linkage group in the finger subdomain of the 66 kDa subunit of HIV RT . Analysis of HIV-1 RT crystal structure by Huang et al. (1998) showed that Lys65 and Arg72, main-chain-NH groups of residues 113 and 114 along with two Mg+ ions are involved in coordinating the incoming triphosphate. In the process, Arg72 donates hydrogen bonds to the α-phosphate and the ε-amino group of Lys65 donates hydrogen bonds to the γ-phosphate. These events lead to the finger closure and trapping of the template strand due to the interaction of L74 with the dNTP and template base . Our data suggest that the side chain (methyl group) in isoleucine (74I) conferred a decreased structural constraint on RT to improve the replication of viruses containing K65R+L74I mutations. In contrast to this the major influence observed with K65R+L74V RT may be during reinitiation and not during processive synthesis [5, 37].
The effect of compensatory mutations on viral replication and RT has been previously analyzed by several laboratories [34, 38, 39]. In an era of combination therapy and the selection of MDR mutations, it is important to assess the interaction among mutations in relation to viral replication fitness and the possible impact on therapy [2, 40–42]. For example, in contrast to the severe replication defect conferred by L74V mutation in the background of K65R [5, 29], RT mutation A62V and S68G have been shown to improve replication capacity of virus when selected in the same genome that contain K65R mutation . Other studies have demonstrated that the RT mutation M184V further decreases replication capacity of K65R viruses by decreasing the ability to incorporate natural dNTPs [32, 40, 43]. In the context of L74I selection, a recent survey of large database revealed that TAMs and M184V are the most commonly observed nucleoside analogue mutations (>25%) followed by L74V/I (11%) and K65R remain stable (3.3%) between 2003-2006 [1, 3, 5]. The significant linkage studies by Parikh et al (2006) had previously demonstrated that while TAMs are rarely observed in combination with K65R their association with L74V/I is more frequent [3, 44]. Another study focusing on the selection parameters for L74V versus L74I mutations showed that the selection of the latter is more frequent under zidovudine and abacavir combination or under tenofovir with the presence of TAMs [27, 45]. They further showed that K103N is also associated with L74I emergence in the absence of other NNRTI mutations (L100I, G190A and Y181C). In contrast, the selection of L74V is mainly associated with the use of didanosine. This study showed that the selection of L74V and L74I is controlled by two independent pathways and it is speculated that the resistance levels and replication capacity of viruses containing these mutations may be different. It is conceivable that the robust RCs of L74I viruses will have an implication in the selection and prevalence of mutant viruses with L74I mutation presumably with thymidine analogue mutations under specific combination of drugs. Our observations that L→I but not L→V change at RT codon 74 in the background of K65R leads to the generation of RT which is much more stable and enough for the enhanced viability of the virus (Figure 1 and Figure 4) is intriguing and needs to be addressed further. Specifically, the impact of emerging L74I in combination of other NRTI-selected mutations should be analyzed. Considering the low level selection of K65R mutation in treatment-experienced patients exposed to abacavir or didanosine, which also select L74V , and the observations that patients with K65R experienced significantly higher rates of virologic suppression than did those with L74V  requires further virological and biochemical investigation to understand the interactions among RT residues at codon 65 and 74 including impact of amino acid polymorphism.
In summary, we demonstrated here that in contrast to L74V, the L74I mutation in the background of K65R results in a replication competent virus due to an increased processivity of RT. As both the double mutants are attenuated in comparison to WT and single point mutants (K65R, L74V and L74I) and RTs containing mutations K65R+L74V or K65R+L74I have decreased processivity, our results provide the explanation for the rarity of these double mutants in clinical settings. Our observations emphasize the significance of better understanding and identification of the novel amino acids of RT that are highly deleterious when mutated, in order to optimize drug regimens during virologic failure, design novel RT inhibitors, and analyze vaccine constructs targeted to specific CD8+ T-cell responses against these targets.
PLS is an Assistant Professor in the Department of Microbiology and Immunology and has more than 15 years of experience in the area of HIV-1 replication fitness. PLS has published key papers in this area that are cited in this manuscript. HBC is a post doctoral associate and is working in the area of HIV replication fitness since Jan. 2008. VN is currently a resident in Family medicine and has worked in the laboratory of PLS for three years. VN has published several papers with PLS in the area of HIV-1 replication fitness. DR is Professor of Medicine at Emory University and Chief of Infectious Diseases at Atlanta VA Medical Center. DR is involved in HIV clinical research since past 20 years. CC is Professor of Medicine at Harvard Medical School and has published several key papers in the area of HIV-1 replication fitness and RT processivity with PLS.
peripheral blood mononuclear cells
human immunodeficiency virus type 1
polymerase chain reaction
thymidine analogue mutations
nucleoside reverse transcriptase inhibitors
non-nucleoside reverse transcriptase inhibitors
This work was supported by VA MERIT Award (PLS), and the US Department of Veterans Affairs. We are thankful to the Department of Microbiology and Immunology for administrative support for this study. We are also thankful to NIH AIDS Research and Reference reagent Program for providing proviral clone pNL4-3, cell lines 293 and HeLa-CD4-LTR-β-galactosidase. Parts of this research were presented at Retroviruses Meeting (May 18-21, 2009), Cold Spring Harbor, NY and Antiviral Drug Resistance 10th Annual Symposium (November 15-18, 2009) at Chantilly, Virginia. We are also thankful for a travel award to HBC though NIH Antiviral Drug Resistance Symposium to attend Antiviral Drug Resistance 10th Annual Symposium (November 15-18, 2009).
- McColl DJ, Chappey C, Parkin NT, Miller MD: Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antiviral Ther 2008, 13: 189-197.Google Scholar
- Miller MD: K65R, TAMS and tenofovir. AIDS Rev 2004, 6: 22-33.PubMedGoogle Scholar
- Parikh UM, Bacheler L, Koontz D, Mellors JW: The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006, 80: 4971-4977. 10.1128/JVI.80.10.4971-4977.2006PubMed CentralView ArticlePubMedGoogle Scholar
- Bazmi HZ, Hammond JL, Cavalcanti SC, Chu CK, Schinazi RF, Mellors JW: In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob. Agents Chemother 2000, 44: 1783-1788. 10.1128/AAC.44.7.1783-1788.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Sharma PL, Nurpeisov V, Rapp K, Skaggs S, Amat di SFC, Schinazi RF: Replication-Dependent 65R→K Reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V. Virology 2004, 321: 222-234. 10.1016/j.virol.2003.11.013View ArticlePubMedGoogle Scholar
- Henry M, Tourres C, Colson P, Ravaux I, Poizot-Martin I, Tamalet C: Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome. J Clin Virol 2006, 37: 227-230. 10.1016/j.jcv.2006.07.001View ArticlePubMedGoogle Scholar
- Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, Miller MD: The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J Acquir Immune Defic Syndr 2008, 48: 428-436. 10.1097/QAI.0b013e31817bbe93View ArticlePubMedGoogle Scholar
- Wirden M, Lambert-Niclot S, Marcelin AG, Schneider L, Ait-Mohand H, Brunet C, Angleraud F, Amard S, Katlama C, Calvez V: Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1 infected patients. AIDS 2009, 23: 95-99. 10.1097/QAD.0b013e328319bc91View ArticlePubMedGoogle Scholar
- Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986, 59: 284-291.PubMed CentralPubMedGoogle Scholar
- Kimpton J, Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J Virol 1992, 66: 2232-2239.PubMed CentralPubMedGoogle Scholar
- Sharma PL, Chatis PA, Dogon AL, Mayers DL, McCutchan FE, Page C, Crumpacker CS: AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay. Virology 1996, 223: 365-369. 10.1006/viro.1996.0488View ArticlePubMedGoogle Scholar
- Sharma PL, Crumpacker CS: Decreased processivity of RT containing a didanosine-selected RT mutation: comparative evaluation of the effect of RT mutations in Leu74Val and Met184Val on viral fitness and RT processivity. J Virol 1999, 73: 8448-8456.PubMed CentralPubMedGoogle Scholar
- Sharma PL, Nettles J, Feldman A, Rapp K, Schinazi RF: Comparative processivity of HIV-1 reverse transcriptases containing K65R, L74V, M184V and 65R + 74V mutations. Antiviral Res 2009, 83: 317-323. 10.1016/j.antiviral.2009.06.002PubMed CentralView ArticlePubMedGoogle Scholar
- Nurpeisov V, Hurwitz SJ, Sharma PL: Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of HIV-1 containing the codon 74 and 184 mutations in reverse transcriptase. J Clin Microbiol 2003, 41: 3306-3311. 10.1128/JCM.41.7.3306-3311.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Sharma PL, Crumpacker CS: Attenuated replication of HIV-1 with a didanosine-selected reverse transcriptase mutation. J Virol 1997, 71: 846-8851.Google Scholar
- Anthony RM, Destefano JJ: In vitro synthesis of long DNA products in reactions with HIV-RT and nucleocapsid protein. J Mol Biol 2007, 365: 310-324. 10.1016/j.jmb.2006.10.007PubMed CentralView ArticlePubMedGoogle Scholar
- Bakhanashvili M: p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. Oncogene 2001, 20: 7635-7644. 10.1038/sj.onc.1204956View ArticlePubMedGoogle Scholar
- Druillennec S, Caneparo A, de Rocquigny H, Roques BP: Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. J Biol Chem 1999, 274: 11283-11288. 10.1074/jbc.274.16.11283View ArticlePubMedGoogle Scholar
- Hehl EA, Joshi P, Kalpana GV, Prasad VR: Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol 2004, 78: 5056-5067. 10.1128/JVI.78.10.5056-5067.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Li X, Quan Y, Arts EJ, Li Z, Preston BD, de Rocquigny H, Roques BP, Darlix JL, Kleiman L, Parnaik MA, Wainberg MA: Human immunodeficiency virus type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA (Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site. J Virol 1996, 70: 4096-5004.Google Scholar
- Negroni M, Buc H: Recombination during reverse transcription: an evaluation of the role of the nucleocapsid protein. J Mol Biol 1999, 286: 15-31. 10.1006/jmbi.1998.2460View ArticlePubMedGoogle Scholar
- Takahashi H, Matsuda M, Kojima A, Sata T, Andoh T, Kurata T, Nagashima K, Hall WW: Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I. Proc Natl Acad Sci USA 1995, 92: 5694-5698. 10.1073/pnas.92.12.5694PubMed CentralView ArticlePubMedGoogle Scholar
- Wilkinson TA, Januszyk K, Phillips ML, Tekeste SS, Zhang M, Miller JT, le Grice SF, Clubb RT, Chow SA: Identifying and characterizing a functional; HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem 2009, 284: 7931-7939. 10.1074/jbc.M806241200PubMed CentralView ArticlePubMedGoogle Scholar
- Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Kuilenburg ABP, van Gennip AH, Berkhout B: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15: 4040-4049.PubMed CentralPubMedGoogle Scholar
- Boyer PL, Hughes SH: Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995, 39: 1624-1628.PubMed CentralView ArticlePubMedGoogle Scholar
- Waters L, Nelson M, Manalia S, Bower M, Powels T, Gazzard B, Stebbing J: The risks and incidence of K65R and L74V mutations and subsequent virologic responses. Clin Infect Dis 2008, 46: 96-100. 10.1086/523001View ArticlePubMedGoogle Scholar
- Wirden M, Malet I, Derache A, Marcelin AG, Roquebert B, Simon A, Kirstetter M, Joubert LM, Katlama C, Calvez V: Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution. AIDS 2005, 19: 630-632. 10.1097/01.aids.0000163942.93563.fdView ArticlePubMedGoogle Scholar
- Back NK, Berkhout B: Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type1 reverse transcriptase. Antimicrob Agents Chemother 1997, 41: 2484-2491.PubMed CentralPubMedGoogle Scholar
- Deval J, Navarro JM, Selmi B, Courcambeck J, Boretto J, Halfon P, Garrido-Urbani S, Sire J, Canard B: A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem 2004, 279: 25489-25496. 10.1074/jbc.M313534200View ArticlePubMedGoogle Scholar
- Gao L, Hanson MN, Balakrishnan M, Boyer PL, Roques BP, Hughes SH, Kim B, Bambara RA: Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J Biol Chem 2008, 283: 9196-9205. 2008 10.1074/jbc.M710148200PubMed CentralView ArticlePubMedGoogle Scholar
- White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK: Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002, 46: 3437-3446. 10.1128/AAC.46.11.3437-3446.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Xu HT, Martinez-Cajas JL, Ntemgwa ML, Coutsinos D, Frankel FA, Brenner BG, Wainberg MA: Effects of K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009, 6: 14.PubMed CentralView ArticlePubMedGoogle Scholar
- Avidan O, Hizi A: The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptases. Nucleic Acids Res 1998, 26: 1713-1717. 10.1093/nar/26.7.1713PubMed CentralView ArticlePubMedGoogle Scholar
- Boyer PL, Gao HQ, Hughes SH: A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at position 74 and 75 via the template primer. Antimicrob Agents Chemother 1998, 42: 447-452.PubMed CentralPubMedGoogle Scholar
- Lacey SF, Larder BA: Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptases, which are significant in nucleoside analog resistance. J Virol 1994, 68: 3421-3424.PubMed CentralPubMedGoogle Scholar
- Jamburuthugoda VK, Santos-Velazquez JM, Skasko M, Operario DJ, Purohit V, Chugh P, Szymanski EA, Wedekind JE, Bambara RA, Kim B: Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage. J Biol Chem 2008, 283: 9206-9216. 10.1074/jbc.M710149200PubMed CentralView ArticlePubMedGoogle Scholar
- Huang H, Chopra R, Verdine GL, Harrison SC: Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase:implications for drug resistance. Science 1998, 282: 1669-1675. 10.1126/science.282.5394.1669View ArticlePubMedGoogle Scholar
- Harris D, Yadav PN, Pandey VN: Loss of polymerase activity due to Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus type-1 reverse transcriptase is compensated by Met to Val substitution within the same motif. Biochemistry 1998, 37: 9630-9640. 10.1021/bi980549zView ArticlePubMedGoogle Scholar
- Olivares I, Sanchez-Merino V, Martinez MA, Domingo E, Lopez-Galindez C, Menendez-Arias L: Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. J. Virol 1999, 73: 6293-6298.PubMed CentralPubMedGoogle Scholar
- Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA: Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS 2007, 21: 665-675. 10.1097/QAD.0b013e3280187505View ArticlePubMedGoogle Scholar
- Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269: 696-699. 10.1126/science.7542804View ArticlePubMedGoogle Scholar
- Richman DD: Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Adv Exp Med Biol 1996, 394: 383-395.View ArticlePubMedGoogle Scholar
- Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, Selmi B, Boretto J, Canard B: Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004, 279: 509-516. 10.1074/jbc.M308806200View ArticlePubMedGoogle Scholar
- Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW: Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 2006, 21: 1405-1414. 10.1097/QAD.0b013e3281ac229bView ArticleGoogle Scholar
- Rhee SY, Liu TF, Holmes SP, Shafer RW: HIV-1 subtype B proteases and reverse transcriptases amino acid covariation. PLoS Comput Biol 2007, 3: e87. 10.1371/journal.pcbi.0030087PubMed CentralView ArticlePubMedGoogle Scholar
- Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, Borroto-Esoda K, Miller MD: Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr 2007, 46: 174-180. 10.1097/QAI.0b013e31814258c0View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.